This investigation has yielded insights into the comparative efficacy, safety, and patient reception of once-weekly GLP-1/GIP agonist treatments and basal insulin in the context of type 2 diabetes mellitus (T2DM). The gene discussed is GIP; the disease is type 2 diabetes mellitus.